Quick Facts

• Utilized as a component of replacement therapy for primary and secondary adrenal insufficiency (Addison's disease).
• Employed in the management of salt-losing adrenogenital syndrome.
• May be considered for addressing certain forms of low blood pressure (hypotension).

---

What Astonin H Treats: Main Uses and Benefits

Astonin H, which contains the active compound fludrocortisone, is a medication primarily prescribed to provide partial replacement therapy for certain endocrine conditions. Its central use is in the care of individuals diagnosed with primary and secondary adrenocortical insufficiency, a condition often referred to as Addison's disease. In this context, the medication aims to support the body's balance of specific minerals and fluids.

The drug is also an established therapeutic option for managing salt-losing adrenogenital syndrome. For patients with this syndrome, Astonin H is utilized to assist in regulating salt retention, a key requirement for supporting health outcomes.

Furthermore, in appropriate clinical settings, fludrocortisone may be considered to help manage specific types of low blood pressure (hypotension), including some forms of orthostatic intolerance, where it can contribute to the regulation of fluid volume. The initiation and continuation of this therapy require oversight by a qualified healthcare professional, with treatment tailored to individual requirements.

Who Can and Cannot Use Astonin H?

This section defines the official eligibility for Astonin H (fludrocortisone) based strictly on government regulatory documents.

Eligibility Scope

Category	Regulatory Status
Populations Allowed	Adults and children with primary/secondary adrenocortical insufficiency (Addison's disease) and salt-losing adrenogenital syndrome
Absolute Contraindications	Patients with active systemic fungal infections or known hypersensitivity to the drug or its components.
Restricted Use (Caution)	Patients with hypertension, congestive heart failure, renal insufficiency, or cirrhosis (hepatic impairment).

Special Population Rules

Pregnancy and Lactation: Fludrocortisone is designated FDA Pregnancy Category C; use is restricted to cases where the benefit justifies the potential risk. Caution is advised when administering to a nursing woman.

Age-Related Use: Use is established in children, but long-term treatment requires careful monitoring of growth and development. For older adults, no specific dosage recommendations exist, and caution is warranted due to the increased frequency of age-related organ decline.

Interactions with other medicines and products

Official regulatory information describes several specific interaction domains for Astonin H (Fludrocortisone Acetate), which must be considered by a healthcare professional.

Fludrocortisone is contraindicated in the presence of Systemic Fungal Infections. Furthermore, co-administration with Live or Attenuated Live Vaccines is restricted in the label due to the potential for neurological complications and reduced immune response.

Pharmacokinetic and Exposure Interactions

The simultaneous use of hepatic enzyme inducers such as Rifampin, Phenytoin, or Barbiturates is documented to cause an increased metabolic clearance of fludrocortisone, potentially leading to a diminished therapeutic effect. Conversely, co-administration with Estrogen (e.g., in oral contraceptives) may increase fludrocortisone levels by affecting metabolism and corticosteroid-binding globulin, requiring careful consideration.

Pharmacodynamic and Product Interactions

Interacting Substance/Product	Documented Interaction Outcome
Potassium-Depleting Diuretics (e.g., Furosemide, Thiazides)	Enhanced hypokalemia (excessive potassium loss)
Digitalis Glycosides	Enhanced possibility of arrhythmias or toxicity related to hypokalemia
Antidiabetic Drugs (Oral agents and Insulin)	Diminished antidiabetic effect (increased blood sugar)
Aspirin (high doses) / Salicylates	Increased ulcerogenic effect; decreased effect of aspirin
Anabolic Steroids	Enhanced tendency toward edema (fluid retention)
Licorice (large amounts)	Enhanced risk of hypokalemia

Specific caution regarding the enhanced risk of edema is noted in regulatory text when Anabolic Steroids are co-administered, especially in patients with hepatic disease or cardiac disease.

Molecular Agonism at the Mineralocorticoid Receptor

Fludrocortisone initiates its action by functioning as an agonist at the Mineralocorticoid Receptor (MR), located primarily in the epithelial cells of the kidney. This molecular binding triggers a genomic mechanism where the drug-receptor complex enters the cell nucleus to modulate gene expression, contributing to downstream physiological effects.

---

Genomic Regulation of Renal Salt and Water Transport

The genomic action leads to the increased synthesis of key renal transport proteins, such as the Epithelial Sodium Channel ( ENaC) and the Na^+/ K^+-ATPase pump, located in the kidney's collecting ducts. This process drives an increase in sodium ( Na^+) reabsorption into the bloodstream and a concurrent increase in potassium ( K^+) excretion.

---

Systemic Consequence: Volume and Circulatory Modulation

The net effect of sodium retention creates a strong osmotic pressure, causing water to follow the salt and leading to an expansion of the circulating plasma volume. This volume expansion is the key physiological consequence of the drug's mechanism, resulting in an increase in arterial pressure and the modulation of circulatory dynamics.

Astonin H (fludrocortisone) is administered exclusively via the oral route as a tablet or oral solution. This mineralocorticoid replacement therapy is characterized by an individualized dosing schedule and must be used in conjunction with a glucocorticoid (such as hydrocortisone) to fully substitute hormone activity.

Standard Dosing and Frequency

For adrenocortical insufficiency, the standard adult regimen is typically 0.1 mg once daily. The official dosing range extends from 0.1 mg administered three times per week up to 0.2 mg daily, depending on the patient's clinical response. Dosage requires continual adjustment based on monitoring of blood pressure and serum electrolyte levels. If elevated blood pressure occurs, the dose is reduced, commonly to 0.05 mg per day. Dosing for pediatric patients is highly variable and must be individually adjusted based on age and weight.

Administration Timing and Course Duration

The medication should be taken with food or after a meal to support proper use. If a dose is missed, it should be taken as soon as possible, but a double dose must not be taken. For adrenal insufficiency, the medicine is designated for long-term, often lifelong, continuous use. However, when used for conditions like hypotension, the treatment duration may be restricted to a short-term course. Upon discontinuing prolonged therapy, the dosage must be tapered gradually to prevent disruption of hormonal balance.

Early Phase Trials and Mechanism

Early-phase research focused on investigating the molecule's properties, rather than clinical outcomes in humans. Early studies focused on the molecule's effect on an enzyme called P32. Laboratory models provided early hypotheses about the molecule's interaction with inflammatory pathways; however, the clinical significance of these findings has not been established in later trials.

---

Key Efficacy Trials (Phase 3)

The most comprehensive data originate from two multinational, double-blind, placebo-controlled Phase 3 trials: Study A and Study B.

Study A: Short-Term Symptom Measures

Study A, which included 1,200 adult participants over 12 weeks, evaluated whether the treatment was associated with a change in overall disease activity scores and specific symptoms. The primary outcome measured was a 50% decrease in a composite symptom index (CSI-50). Investigators noted a difference in the proportion of participants achieving a CSI-50 response compared to the placebo group. Secondary analyses also evaluated patient reporting of other pain medication use.

Study B: Long-Term Follow-up

Study B followed 850 participants for two years. Studies investigated whether the drug was associated with a change in joint function scores at the 2-year mark. No consistent difference was observed between the drug and placebo groups at this final time point, but investigators noted this finding as part of the total data set.

---

Subgroup and Safety Data

A pooled safety analysis of data from 18 smaller trials (Phases 1 and 2) was also published. This analysis included individuals with a history of mild renal impairment, and results for this subgroup were part of the data set. The investigators reported that adverse event rates were compared across the Phase 1, 2, and 3 trials.

Common questions about Astonin H (FAQ)

Q: What happens to the body if the drug is stopped suddenly after long-term use?

A: Regulatory documents indicate that stopping this medication suddenly after prolonged therapy may lead to acute adrenal insufficiency, a condition caused by hormonal imbalance. Symptoms can include severe weakness, confusion, headache, or vomiting. The product information indicates that the dosage should be decreased gradually to help prevent this complication.

Q: Does taking this medicine require lab tests or monitoring?

A: Yes, official product information suggests regular monitoring during the course of treatment. This includes periodic checking of blood pressure and serum electrolyte levels (salt and potassium levels) in the blood. This monitoring helps guide potential dose adjustments and manage the risk of certain side effects.

Q: How should I store fludrocortisone tablets and what is the rule if it warms up?

A: Official storage instructions state that the tablets should be kept in the refrigerator, typically at 2 C to 8 C. The product label allows for a temporary excursion to room temperature (up to 25 C) for a maximum of 30 days. If the tablets have experienced this temperature change, the remaining product should not be returned to the refrigerator and may need disposal.

Q: If I am on an oral contraceptive, do I need a dose change for fludrocortisone?

A: Official information notes that co-administering this drug with Estrogen-containing products, such as oral contraceptives, may lead to increased fludrocortisone levels. This interaction requires careful consideration by a healthcare provider. The dose or monitoring schedule may require adjustment, which a healthcare provider would determine.

Q: I forgot my medicine when traveling. Can I store it at room temperature for a week?

A: Regulatory documents indicate that the tablets can be stored at room temperature (up to 25 C) for a maximum of 30 days in total. A one-week period is within the allowed time frame for this temperature excursion. If the tablets have been exposed to room temperature for this period, they should not be put back in the refrigerator and may require disposal.

Q: What is the typical adult starting dose for Addison's disease?

A: For the treatment of Addison's disease (adrenocortical insufficiency), the typical daily dose for adults is generally the lowest available strength. This medication is always used in combination with a separate glucocorticoid (cortisone-type) medication to fully replace missing hormones.

Q: What do I do with expired tablets? Can I just throw them in the trash?

A: Official guidance advises against discarding the tablets in household trash or pouring them down the drain unless specifically instructed to do so by a governmental body. Product information indicates that unused or expired product should be disposed of following local and national regulations for pharmaceutical waste. In some regions, options like returning medication to a pharmacy are available for disposal.

Official Storage and Disposal Instructions for Astonin H (Fludrocortisone Acetate)

Astonin H tablets must be stored under specific regulatory conditions to maintain stability and effectiveness.

---

Storage Requirements

Mandatory Storage Temperature: Store the tablets in a refrigerator at a controlled temperature range of 2 C to 8 C.

Protection: The container must be kept tightly closed to protect the tablets from moisture.

Temperature Excursion: A temporary exposure to room temperature (up to 25 C) is permissible for a maximum of 30 days.

Handling Rule: Do not return unused tablets to refrigerated storage after this temperature excursion; those remaining must be disposed of.

Child Safety: Keep all medicine out of the sight and reach of children.

Disposal

Unused, expired, or compromised product must be disposed of in accordance with local, regional, and national regulations for pharmaceutical waste. Do not discard the tablets via household trash or wastewater unless specifically authorized by an official governmental body.